- Home
- RYTM vs AKRO Comparison
RYTM vs AKRO Comparison
Compare RYTM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- AKRO
- Stock Information
- Founded
- RYTM 2008
- AKRO 2017
- Country
- RYTM United States
- AKRO United States
- Employees
- RYTM N/A
- AKRO N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- RYTM Health Care
- AKRO Health Care
- Exchange
- RYTM Nasdaq
- AKRO Nasdaq
- Market Cap
- RYTM 3.8B
- AKRO 3.9B
- IPO Year
- RYTM 2017
- AKRO 2019
- Fundamental
- Price
- RYTM $61.33
- AKRO $49.65
- Analyst Decision
- RYTM Strong Buy
- AKRO Strong Buy
- Analyst Count
- RYTM 12
- AKRO 8
- Target Price
- RYTM $76.75
- AKRO $82.50
- AVG Volume (30 Days)
- RYTM 632.6K
- AKRO 1.9M
- Earning Date
- RYTM 05-07-2025
- AKRO 05-12-2025
- Dividend Yield
- RYTM N/A
- AKRO N/A
- EPS Growth
- RYTM N/A
- AKRO N/A
- EPS
- RYTM N/A
- AKRO N/A
- Revenue
- RYTM $136,863,000.00
- AKRO N/A
- Revenue This Year
- RYTM $37.88
- AKRO N/A
- Revenue Next Year
- RYTM $72.84
- AKRO N/A
- P/E Ratio
- RYTM N/A
- AKRO N/A
- Revenue Growth
- RYTM 48.88
- AKRO N/A
- 52 Week Low
- RYTM $35.35
- AKRO $17.86
- 52 Week High
- RYTM $68.58
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- RYTM 51.78
- AKRO 63.34
- Support Level
- RYTM $58.72
- AKRO $44.94
- Resistance Level
- RYTM $63.24
- AKRO $49.29
- Average True Range (ATR)
- RYTM 2.43
- AKRO 3.33
- MACD
- RYTM -0.15
- AKRO 0.67
- Stochastic Oscillator
- RYTM 65.51
- AKRO 86.02
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.